全文获取类型
收费全文 | 58615篇 |
免费 | 4805篇 |
国内免费 | 1544篇 |
专业分类
耳鼻咽喉 | 878篇 |
儿科学 | 1000篇 |
妇产科学 | 987篇 |
基础医学 | 8212篇 |
口腔科学 | 1191篇 |
临床医学 | 5481篇 |
内科学 | 10520篇 |
皮肤病学 | 1424篇 |
神经病学 | 3986篇 |
特种医学 | 3224篇 |
外国民族医学 | 5篇 |
外科学 | 7942篇 |
综合类 | 3504篇 |
现状与发展 | 1篇 |
一般理论 | 14篇 |
预防医学 | 3229篇 |
眼科学 | 1372篇 |
药学 | 5411篇 |
20篇 | |
中国医学 | 1712篇 |
肿瘤学 | 4851篇 |
出版年
2024年 | 72篇 |
2023年 | 442篇 |
2022年 | 688篇 |
2021年 | 2176篇 |
2020年 | 1415篇 |
2019年 | 1644篇 |
2018年 | 1804篇 |
2017年 | 1590篇 |
2016年 | 1862篇 |
2015年 | 2789篇 |
2014年 | 3247篇 |
2013年 | 3553篇 |
2012年 | 5186篇 |
2011年 | 5096篇 |
2010年 | 3366篇 |
2009年 | 2859篇 |
2008年 | 3765篇 |
2007年 | 3481篇 |
2006年 | 3157篇 |
2005年 | 2921篇 |
2004年 | 2327篇 |
2003年 | 2016篇 |
2002年 | 1804篇 |
2001年 | 1240篇 |
2000年 | 1170篇 |
1999年 | 914篇 |
1998年 | 377篇 |
1997年 | 344篇 |
1996年 | 295篇 |
1995年 | 245篇 |
1994年 | 193篇 |
1993年 | 164篇 |
1992年 | 315篇 |
1991年 | 278篇 |
1990年 | 225篇 |
1989年 | 230篇 |
1988年 | 221篇 |
1987年 | 164篇 |
1986年 | 130篇 |
1985年 | 105篇 |
1984年 | 103篇 |
1983年 | 79篇 |
1982年 | 68篇 |
1981年 | 57篇 |
1980年 | 61篇 |
1979年 | 89篇 |
1978年 | 73篇 |
1977年 | 77篇 |
1972年 | 56篇 |
1971年 | 58篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
2.
3.
Sung‐Hyun Hwang Myung‐Chul Kim Sumin Ji Yeseul Yang Yeji Jeong Yongbaek Kim 《Cancer science》2019,110(4):1256-1267
Metformin, a drug for type 2 diabetes mellitus, has shown therapeutic effects for various cancers. However, it had no beneficial effects on the survival rate of human malignant mesothelioma (HMM) patients. The present study was performed to elucidate the underlying mechanism of metformin resistance in HMM cells. Glucose‐starved HMM cells had enhanced resistance to metformin, demonstrated by decreased apoptosis and autophagy and increased cell survival. These cells showed abnormalities in mitochondria, such as decreased ATP synthesis, morphological elongation, altered mitochondrial permeability transition pore and hyperpolarization of mitochondrial membrane potential (MMP). Intriguingly, Mdr1 was significantly upregulated in mitochondria but not in cell membrane. The upregulated mitochondrial Mdr1 was reversed by treatment with carbonyl cyanide m‐chlorophenyl hydrazone, an MMP depolarization inducer. Furthermore, apoptosis and autophagy were increased in multidrug resistance protein 1 knockout HMM cells cultured under glucose starvation with metformin treatment. The data suggest that mitochondrial Mdr1 plays a critical role in the chemoresistance to metformin in HMM cells, which could be a potential target for improving its therapeutic efficacy. 相似文献
4.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
5.
Kenny P. Pang FRCSEd FRCSI Claudio Vicini MD Filippo Montevecchi MD Ottavio Piccin MD MSc Sudipta Chandra MBBS MS Hyung C. Yang MD PhD Vikas Agrawal MS DLO Joseph C. K. Chung FRCS Yiong H. Chan BSc PhD Scott B. Pang Kathleen A. Pang Edward B. Pang Brian Rotenberg MD MPH FRCSC 《The Laryngoscope》2020,130(9):2281-2284
6.
Autoimmune comorbid diseases associated with lichen planus: a nationwide case–control study 下载免费PDF全文
7.
目的:探讨保留肾脏的输尿管部分切除术治疗原发性输尿管癌的长期疗效。方法:回顾性分析1999年3月~2013年2月行保留肾脏的输尿管部分切除术的31例输尿管癌患者临床资料:12例患者行输尿管膀胱再植术,19例行输尿管端端吻合术。随访14~171个月,观察术后尿路肿瘤复发率、患者总体生存率、肿瘤分期及病理分级方面分层生存率等情况。结果:术后尿路肿瘤复发率为19.35%(6/31);总体5年及10年生存率分别为77.41%、58.64%;低肿瘤分期组5年及10年生存率均为86.67%,高肿瘤分期组5年及10年生存率分别为74.93%和54.29%;低病理分级组5年及10年生存率均为76.00%,高病理分级组5年及10年生存率分别为78.26%和48.83%。结论:在严密随访下,输尿管部分切除术可以有效治疗低分期、低分级输尿管癌。 相似文献
8.
9.
10.